Cutting edge technology
Cutting edge technology
NexCalibur is developing technologies that enable:
Highest accuracy of neoantigen identification using multi-omics profiling, proprietary AI pipeline and fast ex vivo validation
Shortest overall vaccine production timeline (3 weeks) and lowest cost ($15,000 for whole treatment) advancing early and combinatorial treatment with highest efficacy
Applicable for both cancer treatment and cancer prevention
We’re making breakthroughs in each critical steps to the “right” neoantigens for cancer treatment vaccine.
We’re making breakthroughs in each critical steps to the “right” neoantigens for cancer treatment vaccine.
We work on preventive vaccine for non-viral cancers as well employing mRNA technologies
We work on preventive vaccine for non-viral cancers as well employing mRNA technologies
NexCalibur has been achieving successes in its path towards the cure
NexCalibur has been achieving successes in its path towards the cure
